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Abstract
Objective: Pulmonary hypertension remains a major clinical problem despite current therapies. In this study, we examine
for the first time a novel pharmacological target, smooth muscle myosin, and determine if the smooth muscle myosin
inhibitor, CK-2019165 (CK-165) ameliorates pulmonary hypertension.
Materials and Methods: Six domestic female pigs were surgically instrumented to measure pulmonary blood flow and
systemic and pulmonary vascular dynamics. Pulmonary hypertension was induced by hypoxia, or infusion of the
thromboxane analog (U-46619, 0.1 mg/kg/min, i.v.). In rats, chronic pulmonary hypertension was induced by monocrotaline.
Results: CK-165 (4 mg/kg, i.v.) reduced pulmonary vascular resistance by 2263 and 2866% from baseline in hypoxia and
thromboxane pig models, respectively (p,0.01 and 0.01), while mean arterial pressure also fell and heart rate rose slightly.
When CK-165 was delivered via inhalation in the hypoxia model, pulmonary vascular resistance fell by 1766% (p,0.05)
while mean arterial pressure and heart rate were unchanged. In the monocrotaline model of chronic pulmonary
hypertension, inhaled CK-165 resulted in a similar (18.063.8%) reduction in right ventricular systolic pressure as compared
with sildenafil (20.364.5%).
Conclusion: Inhibition of smooth muscle myosin may be a novel therapeutic target for treatment of pulmonary
hypertension.
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Introduction
Pulmonary artery hypertension is a serious and progressive
disease of varied etiologies including genetic and environmental
factors that also may be associated with other chronic medical
conditions [1]. Regardless of the underlying condition, a
progressive rise in pulmonary artery pressure and vascular
resistance leads to right heart dysfunction and eventual right
heart failure, exercise intolerance and ultimately death [2].
Prostacyclin and prostaglandin analogues (e.g., epoprostenol,
iloprost, treprostinil), endothelin receptor antagonists (e.g., bosen-
tan, ambrisentan) and phosphodiesterase inhibitors (e.g., sildenafil,
tadalafil) are the three major classes of medications currently
approved for treatment of pulmonary artery hypertension [1,3–5].
Despite the number of currently available therapeutic options,
three year mortality remains high and survival has been estimated
at 87%, 76%, and 67% for years 1, 2 and 3 respectively [6].
Accordingly, there remains a continued need for novel therapeutic
options to treat pulmonary hypertension. The rationale for this
study is to elucidate, for the first time, a novel pharmacological
target, pulmonary arterial smooth muscle myosin.
Smooth muscle myosin is responsible for vascular contraction
and maintenance of vascular tone [7,8]; current pulmonary
vasodilating mechanisms indirectly inhibit smooth muscle myosin
function by acting through second messenger signaling cascades.
The relationship between vascular tone and intravascular pressure
has been well established. Since the mechanical force generated
through the hydrolysis of ATP by smooth muscle myosin is needed
for the generation of vascular tone [8,9], it follows that all
regulatory pathways of vascular tone and intravascular pressure
ultimately converge at smooth muscle myosin. Recently, selective
direct smooth muscle myosin inhibitors capable of blocking ATP
hydrolysis and relaxing vascular smooth muscle have been
developed and we have reported the efficacy of one such inhibitor,
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smooth muscle myosin inhibitors relax vascular smooth muscle by
binding to the myosin enzymatic domain and inhibiting ATP
turnover, leaving smooth muscle myosin in a weak actin binding
state. However, it is unknown whether smooth muscle myosin
inhibitors are able to reduce pulmonary vascular tone in the
setting of pulmonary hypertension. In the current study, we
examined the therapeutic potential of the smooth muscle myosin
inhibitor, CK-2019165 (CK-165, US Patent Application
No. 20098/0275537), delivered either as an intravenous infusion
or by inhalation of a nebulized solution, in porcine and rodent
models of acute pulmonary hypertension. We also compared the
effects of pulmonary vascular smooth muscle myosin inhibition
with the nitric oxide donor, sodium nitroprusside, the prostacyclin
analog, treprostinil, and the phosphodiesterase 5 inhibitor,
sildenafil. We also compared the efficacy of CK-165 to sildenafil
in a rat model of chronic pulmonary arterial hypertension induced
by monocrotaline.
Results
Models of Acute Pulmonary Artery Hypertension in Pigs
Hypoxia model. Hypoxia was achieved by continuous
monitoring and titration of the fraction of inspired oxygen to
10%. This resulted in non-significant increases in heart rate and in
pulmonary blood flow with a significant 2661% reduction in
mean arterial pressure (p,0.01), a 6368% increase (p,0.01) in
mean pulmonary arterial pressure as well as a 104620% (p,0.01)
increase in pulmonary vascular resistance (Figure 1, Table 1).
Thromboxane model. Thromboxane infusion in
anesthetized pigs resulted in non-significant changes in mean
arterial pressure, heart rate and pulmonary blood flow with a
significant 8868% increase (p,0.01) in mean pulmonary arterial
pressure, and a 125618% increase in pulmonary vascular
resistance (p,0.05) (Figure 1, Table 2).
Antihypertensive Effects of CK-165 Compared with
Nitroprusside
Hypoxia Model of Pulmonary Hypertension. Intravenous
delivery of the smooth muscle myosin inhibitor CK-165 (4 mg/kg)
in anesthetized pigs, compared with nitroprusside (2 mg/kg)
resulted in a lesser peak reduction in mean arterial pressure of
1163% vs. 2663% (p,0.01), but with similar peak reductions in
mean pulmonary arterial pressure (3.761 mmHg vs.
5.860.7 mmHg, p=0.056) and pulmonary vascular resistance
(2263 vs. 1565%). These results suggest that similar pulmonary
vascular effects were obtained with the two drugs, with a lower risk
of systemic hypotension with CK-165. Furthermore, a greater
increase in peak pulmonary blood flow was seen with CK-165
(961%) as compared to nitroprusside (462%) (p,0.01) along with
a more sustained effect as compared to nitroprusside. (Figure 2,
Table 1).
When CK-165 (10 mg/ml) and nitroprusside (4 mg/ml) were
delivered via inhalation in the hypoxia model of pulmonary artery
hypertension in anesthetized pigs, they resulted in relatively minor
effects on mean arterial pressure, and similar, but modest effects
on pulmonary artery pressure and vascular resistance (Figure 3),
suggesting that when delivered via inhalation, CK-165 and
nitroprusside have similar effects on pulmonary hypertension.
Thromboxane Model of Pulmonary Hypertension. In
anesthetized pigs, intravenous delivery of CK-165 resulted in a
significantly greater maximal reduction in mean arterial pressure
of 2563% vs. 1464% (p,0.05) compared with nitroprusside
(2 mg/kg). The peak reductions in mean pulmonary arterial
pressure 1765 vs. 1663% were similar, while the decrease in
pulmonary vascular resistance tended to be greater with CK-165
(2866 vs. 1464%, p=0.08), accordingly, as was observed in the
conscious pigs, there was a greater increase in peak pulmonary
blood flow with CK-165 (1563%) as compared to nitroprusside
(162%) (p,0.05). Again the effects of CK-165 were more gradual
in onset and longer lasting as compared with nitroprusside
(Figure 4, Table 2).
Figure 1. Models of pulmonary hypertension. Hemodynamic recordings of hypoxia and thromboxane pulmonary hypertension models. While
the hypoxia resulted in a decrease in arterial pressure and the intravenous infusion of thromboxane resulted in an increase, both methods were able
to increase pulmonary pressure with minor effects on pulmonary blood flow.
doi:10.1371/journal.pone.0036302.g001
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with intravenous delivery of nitroprusside (2 mg/kg) reduced mean
arterial pressure (1062% vs. 862%) and mean pulmonary arterial
pressure similarly (1364v s .1 1 61%) while CK-165 decreased
pulmonary vascular resistance somewhat more (1761%) than
nitroprusside (665%), resulting in a greater increase in peak
pulmonary blood flow seen with CK-165 (1163%) as compared to
nitroprusside (163%) (p,0.05). Furthermore, the effects of CK-165
were more gradual in onset and longer lasting as compared to the
rapid rise and fall seen with nitroprusside (Data not shown).
Rat Model of pulmonary artery hypertension against
treprostinil and sildenafil
In anesthetized rats, pulmonary hypertension was induced by
intravenous infusion of thromboxane (U-46619). Once the right
ventricular systolic pressure (RVSP) and mean arterial pressure
(MAP) were stable CK-165 was delivered via inhalation at 5 mg/
kg (20.468.6%, p,0.01) and 30 mg/kg (58.266.9%, p,0.01),
resulting in a significant reduction in RVSP compared with saline
treated rats by the six minute time point (Figure 5). Furthermore,
when compared against both the prostacyclin analog treprostinil
and the phosphodiesterase 5 inhibitor sildenafil, a similar maximal
reduction of RVSP was achieved with CK-165 (Figure 5).
Model of chronic pulmonary artery hypertension with
monocrotaline in rats
Pulmonary artery hypertension was induced in rats via adminis-
tration of a single dose of monocrotaline (60 mg/kg subcutane-
ously). After two weeks, animals were randomized to receive
100 mg/kg/day sildenafil or no sildenafil for 7 days and at the end
of which the groups were randomized again to receive 30 mg/kg
CK-165 or placebo. CK-165 was able to induce a similar reduction
in RVSP with (2064.5%, p,0.01) or without (1863.8%, p,0.05)
sildenafil compared with the monocrotaline only group (Figure 6).
Ex-vivo demonstration of vaso-relaxation via smooth
muscle myosin inhibition
Pulmonary arteries were isolated from naı ¨ve rats as well as
monocrotaline induced pulmonary artery hypertensive rats and
Table 1. Effects of Hypoxia and Subsequent CK-2019165 or Nitroprusside.
Pre-
Hypertension
Baseline
Pulmonary
Hypertension
baseline Hypoxia Model (CK-165) % change
Hypoxia Model (Nitroprusside) %
change
(n=6) (n=6)
Intravenous
(n=5) Inhalation (n=6)
Intravenous
(n=6) Inhalation (n=6)
Heart Rate (bpm) 12567.7 14669.4 8.761.0%
{ 3.360.8%
{ ## 8.662.7%
{ 20.460.8%
Mean Arterial Pressure (mmHg) 9763.1 7161.8
** 210.762.8%
{ ## 20.661.0% 225.962.5%
{ 2.563.4%
Mean Pulmonary Artery Pressure
(mmHg)
17.860.3 28.861.0
** 213.762.4%
{ 213.963.3%
{ 222.663.4%
{ 212.261.4%
{
Pulmonary Blood Flow (L/min) 2.660.1 (n=5) 2.860.2 (n=5) 9.461.1%
{ ## 1.561.3% (n=5) 4.262.2% (n=5) 1.561.0% (n=5)
Pulmonary vascular resistance
(mmHg/L/min)
4.060.3 (n=5) 8.161.0
** (n=5) 221.962.9%
{ 217.265.7%
{ (n=5) 214.764.7%
{
(n=5)
213.263.1%
{
(n=5)
*p,0.05 Pulmonary Hypertension vs. Pre-Hypertension Baseline.
**p,0.01 Pulmonary Hypertension vs. Pre-Hypertension Baseline.
{p,0.05 Hypertension Baseline vs. Subsequent CK-2019165 or nitroprusside.
{p,0.01 Hypertension Baseline vs. Subsequent CK-2019165 or nitroprusside.
#p,0.05 CK-2019165 vs. nitroprusside.
##p,0.01 CK-2019165 vs. nitroprusside.
doi:10.1371/journal.pone.0036302.t001
Table 2. Effects of Thromboxane and Subsequent CK-2019165 or Nitroprusside in Anesthetized Pigs.
Pre-Hypertension
Baseline
Pulmonary
Hypertension baseline
Thromboxane Peak
(CK-165) % Change
Thromboxane Peak
(Nitroprusside) % Change
(n=5) (n=5) (n=4) (n=5)
Heart Rate (bpm) 12864.3 13066.9 6.762.7% 5.161.7%
{
Mean Arterial Pressure (mmHg) 10065.1 11266.2 224.562.5%
{ # 213.663.6%
{
Mean Pulmonary Artery Pressure (mmHg) 18.560.9 34.761.4
** 217.465.4%
{ 215.663.0%
{
Pulmonary Blood Flow (L/min) 3.260.4 (n=4) 3.060.4 (n=4) 14.8563.4%
{ ## 1.4261.8%
Pulmonary vascular resistance (mmHg/L/min) 4.560.9 (n=4) 10.061.8
* (n=4) 228.265.5%
{ 214.364.2%
{
*p,0.05 Pulmonary Hypertension vs. Pre-Hypertension Baseline.
**p,0.01 Pulmonary Hypertension vs. Pre-Hypertension Baseline.
{p,0.05 Hypertension Baseline vs. Subsequent CK-2019165 or nitroprusside.
{p,0.01 Hypertension Baseline vs. Subsequent CK-2019165 or nitroprusside.
#p,0.05 CK-2019165 vs. nitroprusside.
##p,0.01 CK-2019165 vs. nitroprusside.
doi:10.1371/journal.pone.0036302.t002
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rine. The addition of CK-2018571 (the parent of the more soluble
pro-drug, CK-165) was able to relax phenylephrine induced
contraction of pulmonary arterial rings from both naı ¨ve and
monocrotaline induced pulmonary artery hypertensive rats with a
similar EC50 of 6.0860.03 mM and 6.0860.10 mM, respectively
(Figure 7).
Discussion
Since the final common effector of vascular constriction in
pulmonary hypertension is smooth muscle myosin; it follows that
an agent that relaxed smooth muscle at the level of smooth muscle
myosin would be an effective approach to pulmonary vasodilation.
Indeed, this mechanism appears effective in reducing arterial
pressure in models of systemic hypertension [10]. The major
finding of the current investigation is that the smooth muscle
myosin inhibitors, CK-2019165, a soluble pro-drug of CK-
2018571 were effective in reducing pulmonary vascular resistance
in several models of pulmonary hypertension.
The effectiveness of smooth muscle myosin inhibition was
demonstrated in two acute models of pulmonary hypertension
(hypoxia and thromboxane) in chronically instrumented pigs with
direct and continuous measurements of pulmonary and aortic
arterial pressure, pulmonary blood flow and vascular resistance
and compared to nitroprusside, a nitric oxide donor examined
extensively in animal models of pulmonary hypertension [11–14].
Inhalation of nitric oxide is used in patients with pulmonary
hypertension to establish the degree of acute reversibility and to
reduce pulmonary artery pressure in the setting of adult
respiratory distress syndrome without affecting systemic vascular
tone [15]. The smooth muscle myosin inhibitor, CK-165, achieved
similar efficacy to nitroprusside in these acute models of
pulmonary hypertension.
Inhibition of smooth muscle myosin with CK-165 effectively
reduced pulmonary artery pressure and pulmonary vascular
resistance in both the hypoxia and thromboxane models of
pulmonary hypertension regardless of whether the drug was
delivered via the intravenous or inhalation route. When the drug
was delivered intravenously, there was a fall in systemic arterial
pressure suggesting the drug also affected systemic resistance
vessels. However, when the drug was delivered through inhalation,
this was not observed and the vasodilator effects were localized to
the pulmonary vasculature.
A second goal of this study was to compare the effects of CK-
165 in acute and chronic rat models of pulmonary hypertension.
Smooth muscle myosin inhibition is capable of directly relaxing
pulmonary artery vascular rings derived from rats with chronic
pulmonary hypertension induced by monocrotaline to a similar
degree and potency as those derived from naı ¨ve rats, consistent
with a direct effect on the pulmonary vasculature. When delivered
via nebulization in the thromboxane induced rat model of acute
pulmonary hypertension, CK-165 reduced right ventricular
systolic pressure (RVSP) consistent with a reduction in pulmonary
artery pressure; further, CK-165 was able to reduce the RVSP to a
similar extent (although not similar potency) as that seen with
either treprostinil or sildenafil.
Finally, to address the question of efficacy in a setting where
pulmonary vascular remodeling is present as is found in chronic
pulmonary artery hypertension, we examined the efficacy of CK-
165 in rats with monocrotaline induced chronic pulmonary artery
hypertension. CK-165 reduced RVSP as an acute monotherapy to
Figure 2. Effects of intravenous CK-165 on hypoxia induced pulmonary hypertension. The efficacy of intravenous CK-165 (4 mg/kg) and
nitroprusside (2 mg/kg) were examined and compared in the porcine hypoxia model of pulmonary hypertension. All changes were plotted as percent
change from baseline. The relatively longer half life, the more gradual and greater effects on mean pulmonary vascular resistance and blood flow
were noted. (* p,0.05, ** p,0.01 CK-165 vs. nitroprusside).
doi:10.1371/journal.pone.0036302.g002
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reduction in RVSP was essentially the same when co-administrat-
ed with sildenafil, suggesting that a maximal effect on RSVP had
been attained by each of these therapies.
In conclusion, inhibition of smooth muscle myosin is an effective
means to reduce pulmonary vascular resistance and may be a
potential therapeutic approach for pulmonary hypertension. Its
effects compared with nitroprusside were more gradual and
sustained when delivered intravenously, but quite similar when
delivered by inhalation. Furthermore, it was able to produce
similar effects when compared against both a prostacyclin analog
as well as a phosphodiesterase 5 inhibitor in the case of acute
pulmonary artery hypertension and against a phosphodiesterase 5
inhibitor in the setting of chronic pulmonary artery hypertension.
Based on our results, inhibition of smooth muscle myosin appears
to be efficacious in models of pulmonary hypertension. Although
the duration of action of the current smooth muscle myosin
inhibitor examined in this study may not be sufficient for chronic
therapy in this disease, the current study provides proof of concept
for this novel therapeutic target and its application to the
treatment of pulmonary hypertension.
Materials and Methods
CK-2019165 and CK-2018571 were provided by Cytokinetics,
Inc.
Animal Models
Animals used in this study were maintained in accordance with
the Guide for the Care and Use of Laboratory Animals of the National Health
Institute (NIH, 2010) and New Jersey Medical School Institutional Animal
Care and Use Committee or by the Institutional Animal Care and Use
Committee at Cytokinetics, Inc. This study has been approved by the
New Jersey Medical School Institutional Animal Care and Use Committee
protocol# 08088 and by the Cytokinetics, Inc. Institutional Animal Care
and Use Committee under Protocol CK020-09.
Pig Models. Six domestic female pigs (15–20 kg) were
anesthetized with thiopental (15 mg/kg i.v.) followed by endo-
tracheal intubation and halothane (1.0–1.5 vol%) anesthesia. A left
thoracotomy at the 5
th intercostal space was performed, Tygon
catheters were placed in the descending aorta, pulmonary artery
and left atrium to measure their respective pressures. A Tygon
catheter was also placed in the right atrium and used for drug
administration. A transonic flow probe was placed around the main
pulmonary artery to measure pulmonary blood flow. The chest was
closed and post-operative analgesics were administered until the
animals recovered fully from surgery. Female pigs were chosen over
malepigs dueto anatomical concerns foranimal discomfortwhile in
the sling during the extended experimental time period. All
experiments in pigs were performed under anesthesia except for
the experiments involving thromboxane induced pulmonary hyper-
tension where experiments were performed in both conscious and
anesthetized pigs.
Systemic hemodynamics in pigs were recorded using a Triton
system (Triton, Inc.) and PowerLab data acquisition system
(ADInstruments, Inc.). Aortic, pulmonary artery and atrial
pressure were measured using strain gauge manometers that had
been calibrated with a mercury manometer connected to the fluid-
filled catheters. Pulmonary blood flow was measured with a
Figure 3. Effects of nebulized CK-165 on hypoxia induced pulmonary hypertension. The efficacy of nebulized CK-165 (4 mg/kg) and
nitroprusside (2 mg/kg) were examined and compared in the porcine hypoxia model of pulmonary hypertension. All changes were plotted as percent
change from baseline. When delivered continuously, similar effect profiles are observed between CK-165 and nitroprusside.
doi:10.1371/journal.pone.0036302.g003
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36302Figure 4. Effects of intravenous CK-165 on thromboxane induced pulmonary hypertension. The efficacy of intravenous CK-165 (4 mg/kg)
and nitroprusside (2 mg/kg) were examined and compared in the porcine thromboxane model of pulmonary hypertension. All changes were plotted
as percent change from baseline. The relatively longer half life, the more gradual and greater effects on mean arterial pressure, mean pulmonary
vascular resistance and blood flow were noted. (* p,0.05, ** p,0.01 CK-165 vs. nitroprusside).
doi:10.1371/journal.pone.0036302.g004
Figure 5. Dose response and pharmacodynamics of CK-165 in rats with U46619 induced pulmonary hypertension. CK-165 decreased
RVSP rapidly after nebulization at both 5 mg/kg and 30 mg/kg by 20.468.6 and 58.266.9% at 6 minutes, respectively (p,0.01 compared with
baseline). The maximum decrease in RVSP, Emax, observed with CK-165 (7567.53%) is similar to that seen with the prostacyclin analog, treprostinil
(5868.09%) and the phosphodiesterase 5 inhibitor, sildenafil (6167.65%).
doi:10.1371/journal.pone.0036302.g005
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vascular resistance was calculated: (pulmonary arterial pressure -
left atrial pressure)/pulmonary blood flow. Due to instrumentation
failure not all hemodynamic variables were recorded for all
experiments and animals.
Five to ten days after surgical instrumentation, pulmonary
hypertension was induced with two different methods in the same
animal at different times. 1) Hypoxic pig model: pigs were
intubated, anesthetized with isoflurane, and ventilated at a
reduced fraction of inspired O2. Pulmonary hypertension resulted
after the fraction of inspired O2 was reduced to about 10% by
adjusting the ratio of N2/O2 mixture in the inspiratory limb of the
ventilator. Pulmonary hypertension was defined as a sustained
elevation of mean pulmonary arterial pressure to $25 mmHg
from an averaged baseline level of 18 mmHg. Arterial oxygen
saturation was monitored continuously using a pulse oximeter
Figure 6. The effect of CK-165 and sildenafil in rats with monocrotaline-induced pulmonary hypertension. CK-165 decreased RSVP
following intratracheal nebulization of 30 mg/kg in rats with monocrotaline induced pulmonary artery hypertension by 18.063.8% (p,0.05) when
compared with vehicle treated group. The decrease is similar to that in monocrotaline rats treated with 100 mg/kg/day sildenafil (20.364.5%) for 7
days and treatment with CK-165 does not appear to have additive effects when co-administered with sildenafil.
doi:10.1371/journal.pone.0036302.g006
Figure 7. Determination of EC50 for CK-2018571 in pulmonary artery tissue rings. CK-2018571 inhibits phenylephrine-induced pulmonary
artery contraction in isolated tissue rings from naı ¨ve and monocrotaline-treated rats. Pulmonary artery rings were pre-contracted with 1 mM
phenylephrine and isometric tension was recorded in the presence of increasing concentrations of CK-2018571. CK-2018571 elicited relaxation in
tissues from naı ¨ve rats with pEC50=6.0860.03, and in tissues from monocrotaline-treated rats with pEC50=6.0860.10.
doi:10.1371/journal.pone.0036302.g007
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pigs were placed in a sling and infused intravenously with the
endoperoxide analog of thromboxane, U46619, at 0.1–0.5 mg/kg/
min in the anesthetized state. These pigs were also studied with
this procedure in the conscious state. Pulmonary hypertension was
defined as a stable pulmonary artery pressure of greater than
30 mmHg. The animals were allowed to breathe spontaneously.
In the hypoxia pig model, once the pulmonary arterial pressure
stabilized for 15 min, a volume of 2–3 ml of 10 mg/ml (CK-165)
was nebulized over 4–5 min through the endotracheal tube using
a Pari LC Plus compressed air nebulizer. The nebulizer was
operated at 20 psi which results in an output of ,4.5 L/min.
Sodium nitroprusside (4 mg/ml) was nebulized for the same
duration as a control. After the drugs washed out, i.e., pulmonary
artery pressure and mean arterial pressure returned to baseline
levels and remained stable for 30 min, the smooth muscle myosin
inhibitor CK-2019165 (4 mg/kg) was administered intravenously
as was the positive control sodium nitroprusside (2 mg/kg).
Without prior pharmacokinetic and pharmacodynamic data in
the porcine model, the washout period for the animals was
determined based on results of hemodynamic monitoring and was
determined to be adequate after all hemodynamic variables
returned to baseline and were stable for 30 min. In the
thromboxane model, CK-165 and nitroprusside were adminis-
tered intravenously in separate experiments under both the
conscious and anesthetized states. In all models systemic and
pulmonary vascular changes were monitored and compared.
Rat Models. Male Sprague-Dawley rats (Harlan,
Indianapolis, IN) weighing between 180 and 210 g were housed
in conventional conditions. Acute pulmonary artery hypertension
was induced by continuous intravenous infusion of U-46619 (1 mg/
kg/min). Chronic pulmonary artery hypertension was induced on
day 0 by a single dose of monocrotaline (MCT) (60 mg/kg
subcutaneously) (Sigma-Aldrich, St. Louis, MO). The rats were
randomlyassigned tofiveexperimentalgroups:1)Control;2)MCT;
3) MCT+100 mg/kg/day Sildenafil for 7 days (days 15–21); 4)
MCT+CK-2019165 30 mg/kg (on day 21), as a single nebulized
dose; and 5) MCT+100 mg/kg Sildenafil (days 15–21)+CK-
2019165 30 mg/kg (on day 21), as a single nebulized dose.
Hemodynamic measurements were made following anesthesia
with a ketamine, xylazine and acepromazine cocktail at the dose of
80–100 mg/kg, 10 mg/kg and 1 mg/kg respectively, intra-
muscular. Rats were mechanically ventilated at 60–80 breaths/
minute with a tidal volume of 2.0–3.0 ml/cycle using a Harvard
rodent ventilator. The right ventricular pressure was recorded by
advancing a 4.0 French pressure sensing catheter (Millar, Houston
TX) into the right ventricle via right jugular vein. CK-2019165
was administrated via intra-tracheal nebulization at 30 mg/kg.
For preparation of pulmonary artery tissue rings for in vitro
study, the main branch of pulmonary artery was isolated from
naı ¨ve or monocrotaline (MCT)-treated rats and placed in
oxygenated physiological salt solution. The pulmonary arteries
were cleaned of adherent tissue and cut into rings (2 mm in length)
and suspended in isolated tissue baths (volume 10 ml) containing
oxygenated Krebs–Ringer bicarbonate buffer with the following
composition (in mmol/l): NaCl (118), KCl (4.7), CaCl2 (2.5),
KH2PO4 (1.2), MgSO4 (1.2), NaHCO3 (25), dextrose (11.1) and
disodium calcium edetate (0.026), maintained at 37uC and
bubbled with 95% O2 and 5% CO2. A resting tension of 0.5 g
was applied (determined by preliminary experiments to afford the
optimum tension-length relationship). Following equilibration for
60 minutes, isometric dose response curves were recorded with
increasing concentrations of CK-2018571 in rings pre-contracted
with phenylephrine (1 mM). Results are mean 6 SE, percent of
maximum relaxation to CK-2018571 (Emax) and agonist sensitivity
(pEC50=2logEC50;E C 50 is concentration that evokes 50%
relaxation). Values were determined using non-linear regression
for both naı ¨ve and MCT-treated rat pulmonary arterial rings.
Statistical analysis
Data are expressed as mean6SE. Statistical significance was
determined using a paired two tailed t-test when comparing CK-
165 to baseline. An unpaired t-test was used to compare the peak
responses of CK-165 to nitroprusside. In all experiments, the peak
response time was chosen based on continuous monitoring and
accordingly, in the CK-165 treated hypoxia model the peak
response time was at 5 minutes. Due to a variation in peak times in
the CK-165-treated thromboxane model, the average of 5 and
8 minute responses were used as peak for comparative analysis.
For nitroprusside in the hypoxia model with inhalation delivery,
the peak response time was 5 minutes, in all other pig models the
peak response time was 1 minute. For chronic pulmonary artery
hypertension studies, the statistical significance was determined by
one-way ANOVA followed by Bonferonni’s post-hoc test.
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